Petrelintide for Obesity

(ZUPREME-3 Trial)

This trial tests a new treatment called petrelintide to help manage weight. Participants will follow a reduced-calorie diet and increase physical activity; some will receive petrelintide, while others will receive a placebo (a substance with no active treatment). The goal is to determine if petrelintide is safe and effective for weight loss in individuals who are overweight or obese and have at least one other weight-related health issue, excluding Type 2 Diabetes. This study suits those with a BMI of 30 or more, or 27 with additional weight-related conditions, who have previously tried and not succeeded with dieting. As a Phase 3 trial, this treatment is in the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking weight management solution.

Research has shown that petrelintide, a treatment under study for weight management, appears promising based on earlier studies. One study found that participants taking petrelintide generally did not experience serious side effects, indicating the dose was well tolerated. Those receiving the highest dose lost an average of 8.6% of their body weight, suggesting the treatment's potential effectiveness.

Petrelintide is unique because it offers a new approach to tackling obesity by mimicking the hormone amylin, which helps regulate appetite and body weight. Unlike current treatments, which are often appetite suppressants or metabolic boosters, Petrelintide specifically targets the brain's satiety centers, potentially leading to more natural weight loss without extreme dieting. Researchers are excited about its potential to provide a more balanced and sustainable weight management option with fewer side effects.

Research has shown that petrelintide, which participants in this trial may receive, can significantly aid in weight loss. One study found that individuals using petrelintide lost up to 10.7% of their body weight over 42 weeks, while those on a placebo lost only 1.7%. Another study reported that 34% to 56% of people treated with petrelintide lost at least 10% of their body weight. These findings highlight petrelintide's potential to help manage weight in individuals with obesity. Most participants tolerated it well, with mild side effects like nausea being the most common.⁶⁷⁸⁹¹⁰